After dismal Q2 earnings,Cano Health (NYSE: CANO) is working with JPMorgan and Oppenheimer as it pursues strategic alternatives, sources familiar with the situation tell Axios.
Why it's the BFD: A vestige of 2021's SPAC bonanza, Cano is a cautionary tale.
